1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10913AR
    Danegaptide Hydrochloride (Standard) 943133-81-1 98%
    Danegaptide Hydrochloride (Standard) is the analytical standard of Danegaptide Hydrochloride (HY-10913A). This product is intended for research and analytical applications. Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
    Danegaptide Hydrochloride (Standard)
  • HY-109171R
    Elinzanetant (Standard) 929046-33-3 98%
    Elinzanetant (Standard) is the analytical standard of Elinzanetant. This product is intended for research and analytical applications. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women.
    Elinzanetant (Standard)
  • HY-109171S
    Elinzanetant-d3 98%
    Elinzanetant-d3 (NT-814-d3) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women.
    Elinzanetant-d3
  • HY-109190R
    Seralutinib (Standard) 1619931-27-9 98%
    Seralutinib (Standard) is the analytical standard of Seralutinib (HY-109190). This product is intended for research and analytical applications. Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KiT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
    Seralutinib (Standard)
  • HY-109193R
    Tovinontrine (Standard) 2062661-53-2 98%
    Tovinontrine (Standard) is the analytical standard of Tovinontrine (HY-109193). This product is intended for research and analytical applications. Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively.
    Tovinontrine (Standard)
  • HY-111151R
    AR-9281 (Standard) 913548-29-5 98%
    AR-9281 (Standard) is the analytical standard of AR-9281. This product is intended for research and analytical applications. AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
    AR-9281 (Standard)
  • HY-111655R
    SKA-31 (Standard) 40172-65-4 98%
    SKA-31 (Standard) is the analytical standard of SKA-31. This product is intended for research and analytical applications. SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure.
    SKA-31 (Standard)
  • HY-111827R
    S-1-Propenyl-L-cysteine (Standard) 52438-09-2
    S-1-Propenyl-L-cysteine (Standard) is the analytical standard of S-1-Propenyl-L-cysteine. This product is intended for research and analytical applications. S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model. S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway. S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine (Standard)
  • HY-112499S
    Menaquinone-7-d7 1233937-31-9 98%
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS).
    Menaquinone-7-d7
  • HY-112868A
    ABH 222638-65-5 98%
    ABH is an orally active arginase inhibitor (Ki = 8.5 nM). ABH promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis.
    ABH
  • HY-113168R
    Butyrylcarnitine (Standard) 25576-40-3 98%
    Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine (HY-113168). This product is intended for research and analytical applications. Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer.
    Butyrylcarnitine (Standard)
  • HY-113341R
    7β-Hydroxycholesterol (Standard) 566-27-8 98%
    7β-Hydroxycholesterol (Standard) is the analytical standard of 7β-Hydroxycholesterol. This product is intended for research and analytical applications. 7β-Hydroxycholesterol is an oxysterol that derived by the oxidation of cholesterol. 7β-hydroxycholesterol can induce cellular oxidative stress, apoptosis, and necrosis, resulting in cytotoxicity. 7β-hydroxycholesterol has antitumor activity.
    7β-Hydroxycholesterol (Standard)
  • HY-113342R
    7-Ketocholesterol (Standard) 566-28-9 98%
    7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis).
    7-Ketocholesterol (Standard)
  • HY-113402B
    Gamma-glutamylcysteine ammonium 98%
    Gamma-glutamylcysteine ammonium (γ-Glu-Cys ammonium) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine ammonium activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine ammonium regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine ammonium is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
    Gamma-glutamylcysteine ammonium
  • HY-113466R
    4-Hydroxynonenal (Standard) 75899-68-2
    4-Hydroxynonenal (Standard) is the analytical standard of 4-Hydroxynonenal. This product is intended for research and analytical applications. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.
    4-Hydroxynonenal (Standard)
  • HY-113517R
    Normetanephrine (Standard) 97-31-4
    Normetanephrine (Standard) is the analytical standard of Normetanephrine. This product is intended for research and analytical applications. Normetanephrine is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Hypertension.
    Normetanephrine (Standard)
  • HY-114252R
    Strophanthidin (Standard) 66-28-4
    Strophanthidin (Standard) is the analytical standard of Strophanthidin. This product is intended for research and analytical applications. Strophanthidin is a naturally available cardiac glycoside. Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal. Strophanthidin increases both diastolic and systolic intracellular Ca2+ concentration.
    Strophanthidin (Standard)
  • HY-114348R
    N,N'-Diacetyl-L-cystine (Standard) 5545-17-5
    N,N'-Diacetyl-L-cystine (Standard) is the analytical standard of N,N'-Diacetyl-L-cystine. This product is intended for research and analytical applications. N,N'-diacetyl-L-cystine (DiNAC) is the disulphide dimer of N-acetylcysteine with immunomodulating properties. N,N'-diacetyl-L-cystine is a potent, orally active modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. N,N'-diacetyl-L-cystine also has antiatherosclerotic effects in Watanabe-heritable hyperlipidemic rabbit (WHHL) rabbits.
    N,N'-Diacetyl-L-cystine (Standard)
  • HY-114674A
    Atrasentan sodium 178738-96-0 98%
    Atrasentan sodium is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA.
    Atrasentan sodium
  • HY-116084R
    Trimethylamine N-oxide (Standard) 1184-78-7 98%
    Trimethylamine N-oxide (Standard) is the analytical standard of Trimethylamine N-oxide. This product is intended for research and analytical applications. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
    Trimethylamine N-oxide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity